Monash University Malaysia has renewed its three-year Memorandum of Understanding with Agilent Technologies, marking a new chapter in a partnership that has supported scientific progress for fifteen years.

The signing also introduced the newly rebranded MUMPMP-Agilent Biodiscovery Hub, a facility designed to strengthen multi-omics research and support work in discovery science and precision health.

The event was held at the university and gathered senior figures from both organisations. It
underscored a shared direction to expand scientific capability, strengthen training, and build
collaborations that serve Malaysia and the region.

In a press release shared by Monash University with PP Health Malaysia (PPHM), Dr Syafiq Asnawi, Senior Lecturer in Biomedical Science and Director of the Department of Molecular Epidemiology & Translational Medicine and the MUM Proteomics & Metabolomics Platform, said the partnership sets a new benchmark for collaborative innovation. “This collaboration reflects Monash University Malaysia’s commitment to delivering world-class research infrastructure that advances discovery and benefits our communities. The MUMPMP– Agilent BioDiscovery Hub strengthens Monash’s position as a regional leader in proteomics, metabolomics, and biotechnology innovation. By combining Agilent’s state-of-the-art technologies with Monash’s research excellence and multidisciplinary ecosystem, we are empowering our scientists and partners to drive solutions for Malaysia and the wider Asia-
Pacific region.”

Agilent also reaffirmed its direction for the collaboration. “At Agilent, we support Monash University in enhancing biological research through proteomics, metabolomics and lipidomics. Our renewed collaboration with Monash University Malaysia continues our 15-year collaboration and positions Agilent as a leader in biotechnology innovation. The BioDiscovery Hub will drive scientific progress, talent development, and creating long-term value for customers and partners,” said Bharat Bhardwaj, Agilent’s vice president of Sales for Asia Pacific.

The Monash–Agilent partnership began in 2010 with the university’s first LC-MS/MS laboratory. It has since grown into a broad research ecosystem supporting proteomics, metabolomics, and multi-omics studies. Each phase of development has added new capability and expanded access for researchers across Monash Malaysia and partner institutions.

The BioDiscovery Hub builds on this foundation. It houses Agilent’s latest analytical platforms,
including high-resolution mass spectrometry and advanced liquid chromatography systems.
These tools will support projects ranging from biomarker discovery to clinical and translational research. The facility also serves as a training centre for early-career scientists, strengthening expertise across the region.

Research programs that have grown from the collaboration include work in cardiomyopathy proteomics with the National Heart Institute and microbiome metabolomics with the School of
Pharmacy and Amway Malaysia. Multi-omics efforts supported by the platform continue to
deepen understanding of health and disease in Malaysian and regional populations.

The event concluded with a presentation on the partnership’s journey, the signing of the
renewed agreement, and a short celebration with attendees from the Jeffrey Cheah School of
Medicine and Health Sciences, Monash University Malaysia, Agilent Technologies, researchers, and operational teams.

With the renewed MOU and the launch of the BioDiscovery Hub, Monash University Malaysia
and Agilent Technologies are positioned to deepen their contribution to scientific advancement, strengthen Malaysia’s research capability, and support projects that improve health outcomes across the region